AstraZeneca (AZN) Gets a Sell from Deutsche Bank
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on AstraZeneca, with a price target of £105.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Papadakis is a 4-star analyst with an average return of 3.5% and a 52.09% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Novo Nordisk, AstraZeneca, and Novartis AG.
Currently, the analyst consensus on AstraZeneca is a Moderate Buy with an average price target of p14,553.48.
Based on AstraZeneca’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of p15.19 billion and a net profit of p2.53 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p1.47 billion
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca’s Saphnelo Gains EU Approval for Self-Administration in Lupus Treatment
- AstraZeneca’s Enhertu Approved for HER2-Positive Breast Cancer
- AstraZeneca says Enhertu plus pertuzumab approved by FDA for 1st line treatment
- AstraZeneca confirms FDA approves Enhertu combo for certain breast cancers
- FDA approves Enhertu with pertuzumab for certain HER2-positive breast cancer
